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Myeloablative single-unit umbilical cord blood transplantation (sUCBT) using busulfan, thiotepa, ﬂudarabine,
and antithymocyte globulin (Grupo Español de Trasplante Hematopoyético [GETH]-2005 protocol) resulted in
high rates of engraftment and high antitumor activity. We designed a new graft-versus-host disease
prophylaxis, substituting long-term steroids with mycophenolate mofetil together with a slight reduction of
antithymocyte globulin (GETH/Gruppo Italiano Trapianto Midollo Osseo [GITMO]-2008 protocol). The results
in 145 consecutive patients were compared with those obtained in 88 patients from the previous GETH-2005
trial. The cumulative incidence (CI) of myeloid engraftment at 60 days for patients in the GETH-2005 and
GETH/GITMO-2008 trials was 94% and 88%, respectively, at a median time to neutrophil recovery of 19 and
23 days, respectively (P < .0001). In the multivariable analyses, platelet engraftment, acute and chronic graft-
versus-host disease, nonrelapse mortality, relapse, and event-free survival were not signiﬁcantly different.
The 3-year event-free survival rate in the GETH/GITMO-2008 trial was 66%, 31%, and 25% for patients
transplanted in early, intermediate, and advanced stages of the disease, respectively (P < .0001). This study
conﬁrms that myeloablative sUCBT using busulfan-based conditioning is a valuable strategy for patients with
hematological malignancies. The use of mycophenolate mofetil apparently had an adverse effect on myeloid
engraftment, and therefore a cautious use of this agent is warranted in the UCBT setting.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Single-unit umbilical cord blood transplantation (UCBT)
from an unrelated donor using busulfan, thiotepa, ﬂudar-
abine, and antithymocyte globulin (ATG) as the myeloa-
blative conditioning regimen (UCBT-GETH-2005 protocol)
has previously reported high rates of engraftment with fast
neutrophil recovery and high antitumor activity in patients
with high-risk hematologic malignancies [1]. This strategy
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13.07.004Hematopoyético (GETH) was, however, associated with
substantial morbidity and mortality, mainly due to oppor-
tunistic infections.
To improve the outcome of the previous strategy, a new
trial (UCBT-GETH/Gruppo Italiano Trapianto Midollo Osseo
[GITMO]-2008) was designed to decrease infection-related
mortality rate. With this objective in mind, the long-term
steroid therapy previously used for graft-versus-host dis-
ease (GVHD) prophylaxis was substituted by a short course of
mycophenolate mofetil (MMF) and a slightly reduced dose of
ATG. In addition, the minimum cell dose threshold in the
GETH/GITMO-2008 protocol did not take into account the
recipient’s body weight but only the total dose of the unit,
with total nucleated cells (TNCs) >150  107 and CD34þ
cells >70  105 being the minimum required.
Transplantation.
J. Sanz et al. / Biol Blood Marrow Transplant 19 (2013) 1387e13921388This study compares the results obtained in 2 consecutive
cohorts of patients with hematological malignancies with
2 different protocols (GETH-2005 and GETH/GITMO-2008)
that differed only in the above-mentioned changes in
GVHD prophylaxis after single-unit UCBT from an unrelated
donor using a chemotherapy-based myeloablative condi-
tioning regimen.
METHODS
Eligibility Criteria
Patients with high-risk hematological malignancy requiring urgent
hematopoietic cell transplantation and lacking a suitable related donor (HLA
identical or 1-antigen mismatched) were eligible for enrollment. The insti-
tutional review board approved the protocol, and written informed consent
was obtained from all patients according to the Declaration of Helsinki.
Protocol was registered on the EudraCT with code 2008-000927-24.
Cord Blood Unit Selection
Graft selection required UCB 4/6 HLAmatchedwith the recipient (HLA
class I antigens [A and B] at antigen level and class II antigens [DRB1] at allele
level resolution DNA typing). Cell dose was considered the most important
criteria for unit selection. In the GETH-2005 protocol, TNCs> 2 107/kg and
CD34þ cells> .6 105/kg or TNCs> 1.5107/kg and CD34þ cells> 1105/
kg were required. For adults included in the GETH/GITMO-2008 protocol,
the cell dose did not take into account the recipient’s body weight but only
the total dose of the unit, with TNC> 150  107 and CD34þ cells > 70  105
being the minimum required. When the UCB units had a similar cell dose,
a higher degree of HLA match was preferred.
Conditioning Regimen and GVHD Prophylaxis
All patients received myeloablative conditioning regimen with thiotepa
5 mg/kg/day on days e7 and e6, i.v. busulfan 3.2 mg/kg/day as a single daily
dose on days e5 toe3, and ﬂudarabine 50 mg/m2/day on days e5 toe3.The
busulfan dose was adjusted in patients weighing < 34 kg to achieve a total
dose of 12 mg/kg, 14.4 mg/kg, 13.2 mg/kg, and 11.4 mg/kg in patients
weighing <9 kg, 9 to 16 kg, 17 to 23 kg, and 24 to 34 kg, respectively. Rabbit
ATG (Thymoglobulin, Sangstat/Genzyme, Lyon, France) was added at
different doses according to the trial as follows: 2 mg/kg/day on days e5 to
e2 in the GETH-2005 and 2 mg/kg/day on days e4 to e2 in the GETH/
GITMO-2008 trial.
For GVHD prophylaxis, all patients received cyclosporine starting on day
e1 at a dose of 1.5 mg/kg/12 hours i.v., followed by 3 to 5 mg/kg/12 hours
p.o. when oral intakewas possible. A slow tapering started between dayþ90
andþ180 to discontinue on dayþ180 or before if feasible. In the GETH-2005
protocol, cyclosporine was combined with a long-course prednisone con-
sisting of .5 mg/kg/day on days þ7 to þ14 and 1 mg/kg/day on days þ14
to þ28, with slow tapering to discontinue on day þ180 in adults or day þ90
in patients younger than 14 years. In the GETH/GITMO-2008 trial, predni-
sone was replaced by MMF, starting on day e1 at a dose of 15 mg/kg/
12 hours i.v. or orally from onset of oral intake until day þ30.
Supportive Care and GVHD Treatment
Patients were nursed in HEPA-ﬁltered rooms. Prophylaxis of busulfan-
induced neurologic toxicity with diphenylhydantoin, clonazepam, or lor-
azepam was administered according to the current protocols at each site.
Granulocyte colony-stimulating factor 5 mg/kg/day was administered
subcutaneously from dayþ7 until neutrophil engraftment. Antibacterial and
antifungal prophylaxis was given following institutional policies. Bacterial
prophylaxis with oral ciproﬂoxacin was recommended during neutropenia
or until the start of broad-spectrum antibiotics. A mold-active azole (itra-
conazole or voriconazole) was also recommended until day þ100 or when-
ever the patient was given steroids for the treatment of GVHD. Prophylaxis
against Pneumocystis jiroveci consisted of cotrimoxazole from day 10 to
day 2 and then was restarted after engraftment 2 days a week and main-
tained for a minimum of 1 year or until immunosuppressive therapy was
stopped. Pentamidine was used if cotrimoxazole was contraindicated. All
blood products were irradiated and leukocyte depleted. Cytomegalovirus
(CMV)-seropositive patients received high-dose acyclovir 500mg/m2/8 h i.v.
until neutrophil recovery. Thereafter, some institutions followed a preemp-
tive approach with PCR monitoring, whereas others administered valganci-
clovir prophylactically as previously described elsewhere [2]. Intravenous
nonspeciﬁc immunoglobulin were recommended at a dose of 500 mg/kg
weekly until day þ100 and then monthly during the ﬁrst year after
transplantation.
Patients who developed acute GVHD received ﬁrst-line therapy with
methylprednisolone at doses ranging from 2 to 20 mg/kg/day followed bygradual tapering, according to institutional policy. Chronic GVHD was
treated with prednisone 1 mg/kg/day.
Deﬁnitions
Myeloid engraftment was deﬁned as an absolute neutrophil count of
.5  109/L for 3 or more consecutive days. Platelet engraftment was deﬁned
as a platelet count of 20  109/L or higher, without transfusion support, for
7consecutive days. Patients who survived more than 28 days after trans-
plantation and who failed to achieve myeloid engraftment were considered
as graft failure. The time to myeloid or platelet engraftment was deﬁned as
the time required to reach the ﬁrst day of engraftment. Acute and chronic
GVHD were deﬁned and graded according to standard criteria [3-5].
Disease status at the time of transplantation was classiﬁed as follows:
1. Early stage: acute leukemia, myelodysplastic syndrome, and lym-
phoma in the ﬁrst complete response (CR1), untreated myelodys-
plastic syndrome with <5% blasts, and/or CML in the ﬁrst chronic
phase
2. Intermediate stage: acute leukemia, lymphoma, or myelodysplastic
syndrome in a second or further CR and CML in a second or further
chronic or accelerated phase
3. Advanced stage: acute leukemia and lymphoma not in remission,
CML in blast crisis, and untreated refractory anemia with excess
blasts
Nonrelapse mortality (NRM) was deﬁned as death from any cause
without evidence of relapse. For event-free survival (EFS), relapse, death,
and graft failure were considered as treatment failure.
Statistical Analysis
The primary objective was to analyze outcomes of patients included in
GETH/GITMO-2008 trial and make an historical comparison with the
previous GETH-2005 trial. A secondary objective was to analyze the risk
factors for different outcomes including all patients from both trials. Patient
and transplant characteristics fromdifferent series were compared using the
chi-square test for categorical variables and the Wilcoxon rank-sum test for
continuous variables. The probabilities of engraftment, NRM, GVHD, and
relapse were estimated by the CI method (marginal probability) [6].
For CI analyses of engraftment and relapse, death in CR was considered
as a competing cause of failure. Relapse and death were considered
competing events for GVHD, whereas relapse was the competing event for
NRM. Unadjusted time-to-event analyses were performed using the Kaplan-
Meier estimate [7] and, for comparisons, log-rank tests [8]. Patient follow-up
was updated on November 15, 2012.
A Cox proportional hazards model [9] or the Fine and Gray method for
competing events [10] were used for multivariable analysis using variables
with P < .10 for each endpoint. Data from both protocols were put together
for analysis of prognostic factor. Variables considered for prognostic factor
analysis were type of UCBT protocol, age, sex, recipient body weight, recip-
ient CMV serology, disease status at transplantation, previous autologous
stem cell transplantation (SCT), HLA compatibility considering low-
resolution typing for class I and high-resolution typing for class II antigens,
ABO blood groupmismatch, donorerecipient sexmatch, and the numbers of
TNCs and CD34þ cells at time of infusion.
When comparing both trials, the ﬁnal model was adjusted for the
differences between the 2 arms. Center effect was measured for all
outcomes. Continuous variables were dichotomized at the most discrimi-
nant cut-off point for each outcome. Statistical analysis were conducted
using R version 2.12.2 (The CRAN project) with packages, survival v2.36-10,
Design 2.3-0, prodlim v1.2.1 and cmprsk v2.2-2 [11].
RESULTS
Patient Accrual and Characteristics
From June 2007 to July 2012, 145 consecutive patients
underwent myeloablative UCBT from an unrelated donor
with the GETH/GITMO-2008 protocol at 10 Spanish institu-
tions within GETH and 5 Italian institutions within GITMO.
Table 1 shows the main characteristics of the patients
included in this trial and, for comparison, those of the
patients included in the previously reported GETH-2005 trial
[1]. Patient and disease characteristics were similar in both
groups. Most patients had acute leukemia in both trials. Fifty-
seven of 60 patients transplanted in the early stage of the
disease in the GETH/GITMO-2008 cohort had acute leukemia
in CR1, 1 patient had refractory anemia with excess blasts
Table 2
Graft- and Transplantation-Related Characteristics*
GETH-2005 GETH/
GITMO-2008
P
HLA compatibility, no. (%)* .002
6 of 6 8 (9) 14 (10)
5 of 6 36 (41) 25 (17)
4 of 6 44 (50) 105 (73)
ABO blood group mismatch, no. (%) .01
Major 27 (31) 31 (22)
Minor 32 (36) 35 (24)
None 29 (33) 78 (54)
Donorerecipient sex match, no. (%) .37
Maleemale 21 (24) 44 (31)
Maleefemale 26 (30) 30 (21)
Femaleemale 24 (27) 36 (25)
Femaleefemale 17 (19) 34 (24)
No. of nucleated cells before
freezing  107/kg, median (range)
3.0 (1.8-32) 3.8 (1.7-16.7) .82
No. of nucleated cells
infused  107/kg, median (range)
2.4 (1.4-32) 3.2 (.8-12.4) .42
No. of CD34 þ cells before
freezing  105/kg, median (range)
1.7 (.7-19) 2 (.4-11.9) .40
No. of CD34 þ cells
infused  105/kg, median (range)
1.4 (.1-31) 1.5 (.1-11.7) .94
* Percentages may not sum to 100 because of rounding
Table 3
Comparison of GETH-2005 and GETH/GITMO-2008 Transplant Outcomes
Outcome GETH 2005
(95% Conﬁdence
Interval)
GETH/
GITMO- 2008
(95% Conﬁdence
Interval)
P
Myeloid engraftment,
CI at 60 d (%)
94 (89-99) 88 (82-93) <.0001
Platelet engraftment,
CI at 180 d (%)
81 (72-89) 73 (66-80) .6
Acute GVHD grades II-IV,
CI at 100 d (%)
29 (19-39) 26 (18-34) .4
Acute GVHD grades III-IV,
CI at 100 d (%)
19 (11-28) 12 (6-17) .1
Chronic extensive GVHD,
3-yr CI (%)
29 (19-40) 15 (8-22) .02
NRM, 3-yr CI (%) 43 (33-54) 33 (25-40) .2
Relapse, 3-yr CI (%) 16 (8-24) 20 (14-27) .4
3-Yr EFS, (%) 40 (30-51) 42 (34-52) 1
Table 1
Characteristics of Patients*
GETH-
2005
GETH/
GITMO-2008
P
No. of patients 88 145
Age group, no. (%) .56
20 yrs 29 (33) 45 (31)
21-30 yrs 19 (22) 25 (17)
31-40 yrs 22 (25) 31 (21)
>40 yrs 18 (20) 44 (30)
Sex, no. (%) .21
Male 45 (51) 80 (55)
Female 43 (49) 65 (45)
Weight, kg .61
Median 66 62
Range 7-104 8-108
Diagnosis, no. (%) .56
Acute myelogenous leukemia 38 (43) 61 (42)
Acute lymphoblastic leukemia 36 (41) 53 (37)
Lymphoma (non-Hodgkin
and Hodgkin)
9 (9) 12 (8)
Chronic myeloid leukemia 1 (1) 9 (6)y
Myelodysplastic syndrome 4 (5) 6 (4)
Others 1 (1)z 4 (1)x
Disease stage at transplant, no. (%) .35
Early 45 (51) 60 (41)
Intermediate 24 (27) 48 (33)
Advanced 19 (22) 37 (26)
Previous autologous transplant 16 (18) 20 (14) .48
CMV seropositive recipients, no. (%) 69 (78) 114 (79) .43
Time of follow-up, mo <.001
Median 61 44
Range 8-85 1-60
* Percentages may not sum to 100 because of rounding.
y Six in second chronic phase, 1 in ﬁrst accelerated phase, 1 in third
accelerated phase, and 1 in ﬁrst chronic phase after failure of tyrosine kinase
inhibitors).
z One plasma cell leukemia.
x Two multiple myeloma, 2 myeloﬁbrosis.
J. Sanz et al. / Biol Blood Marrow Transplant 19 (2013) 1387e1392 1389type 2 in CR1,1 patient had chronicmyelogenous leukemia in
the ﬁrst chronic phase after failure of tyrosine kinase inhib-
itors, and the remaining patient had anaplastic T cell lym-
phoma in CR1 after second-line therapy.
Cord Blood Unit and Transplant Characteristics
Table 2 shows the characteristics of the cord blood units
and those related to the transplantation procedure in both
trials. Compared with GETH-2005 protocol, patients in the
GETH/GITMO-2008 protocol received grafts with higher HLA
disparity (P ¼ .002) and more ABO compatibility (P ¼ .01).
Cell content of the grafts was similar in both groups.
GETH/GITMO-2008 Protocol Outcomes
Transplant outcomes of GETH/GITMO-2008 and GETH-
2005 trials are summarized in Table 3.
Myeloid and platelet engraftment
Five patients died early at a median of 12 days (range, 5 to
19) after UCB infusion without evidence of myeloid engraft-
ment (3 bacterial and 2 fungal infections). Thirteen patients
had primary graft failure. Of these, 6 patients died during
pancytopenia, 4 patients had autologous reconstitution after
autologous back-up progenitor cell infusion (2 patients died of
relapse after 10 months and 2 patients are alive and disease-
free after 44 and 49 months, respectively), and 3 patients
received urgent allogeneic SCT from a haploidentical family
donor (1 patient died of relapse after 20months and2patients
are alive and disease-free after 48 and 60 months, respec-
tively). The remaining 127 patients experienced myeloidengraftment at a median of 23 days (range,11 to 53). The CI of
myeloid engraftment at 60 days was 88%.
Of the 127 patients withmyeloid engraftment, 21 patients
died or relapsed between 23 and 140 days after trans-
plantation without platelet engraftment. The remaining 106
patients had platelet engraftment at a median time of
43 days (range, 21 to 138). The CI of platelet engraftment was
73% at 180 days.
Acute and chronic GVHD
Acute GVHD occurred in 53 of 127 assessable patients.
The clinical grading of acute GVHDwas grade I in 20 patients,
grade II in 18 patients, grade III in 9 patients, and grade IV in 6
patients. Themedian time to the development of acute GVHD
grade II to IV was 24 days (range, 10 to 79). The skin was
involved in 45 patients (grade I in 21, grade II in 16, grade III
in 8), the gut in 24 patients (grade I in 14, grade II in 2, grade
III in 1, and grade IV in 1), and the liver in 15 patients (grade I
in 6, grade II in 1, grade III in 3, and grade IV in 5). The CI of
grades II to IV and grades III to IV acute GVHD at day 100 after
UCBT was 26% and 12%, respectively.
Table 4
Causes of Death
GETH-2005
n (%)
GETH/GITMO-2008
n (%)
P
All cause mortality 54 (61) 84 (58) .7
Relapse 15 (17) 30 (21) .6
Infections 23 (26) 26 (18) .2
Bacterial 11 (12) 9 (6) .1
Fungal 3 (3) 5 (3) 1
Viral 5 (6) 8 (6) 1
Mixed 2 (2) 1 (1) .6
Parasitic 2 (2) 1 (1) .6
Not documented 0 (0) 2 (1) .5
Noninfectious NRM 17 (19) 28 (19) .9
Figure 1. Kaplan-Meier estimate of EFS according to disease status at time of
UCBT for patients included in the GETH/GITMO-2008 trial.
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It was limited in 26 patients and extensive in the remaining
15 patients. The median time to the development of chronic
GVHD was 153 days (range, 86 to 825). The 3-year CI of
overall and extensive chronic GVHD was 40% and 15%,
respectively.
NRM and causes of death
Fifty-four patients died without prior relapse at a median
of 80 days after transplantation (range, 4 to 1352). The CI of
NRM at 100 days, 180 days, and 3 years was 15%, 22%, and
33%, respectively.
The causes of death are summarized in Table 4. Distri-
bution of causes of death was similar for patients in the
GETH-2005 and GETH/GITMO-2008 trials.
Relapse and survival
The median follow-up for surviving patients in the GETH/
GITMO-2008 and GETH-2005 trials was 44 months (range, 7
to 60) and 61 months (range, 8 to 85), respectively. Thirty-
four patients relapsed at a median time of 158 days (range,
13 to 1279). The 3-year CI of relapse was 20%.
Fifty-seven patients remained alive and disease free after
UCBT at the last follow-up (range, 7 to 60 months). The
overall EFS and overall survival at 3 years was, respectively,
42% (95% conﬁdence interval, 34% to 52%) and 44% (95%
conﬁdence interval, 35% to 52%). The 3-year EFS was 66%,
31%, and 25% for patients transplanted in early, intermediate,
and advanced stages of the disease, respectively (P < .0001)
(Figure 1). The 3-year overall survival was 67%, 31%, and
25% for patients transplanted in early, intermediate, and
advanced stages of the disease, respectively (P < .0001).
Analysis of Risk Factors
For the purposes of this study, the analysis of risk factors
was carried out in the whole series, including all patients of
both trials (GETH-2005 and GETH/GITMO-2008). Table 5
shows variables that inﬂuenced transplant outcomes in
multivariable analysis.
Myeloid engraftment
In the multivariable analysis, the only variables that
inﬂuenced myeloid engraftment were UCBT protocol (rela-
tive risk [RR], 1.66; 95% conﬁdence interval, 1.24 to 2.22;
P ¼ .0007) and CD34þ cell dose (RR, 1.72; 95% conﬁdence
interval, 1.17 to 2.53; P ¼ .0006). The CI of myeloid engraft-
ment for patients in the GETH-2005 and GETH/GITMO-2008
protocols at 60 days was 94% and 88%, at a median time
to neutrophil recovery of 19 and 23 days, respectively
(P < .0001) (Figure 2). For patients who received cord bloodunits above and below the best cut-off of 1.4  105 CD34þ
cells/kg, the CI of myeloid engraftment at 60 days was 91%
and 89%, at a median time to neutrophil recovery of 20 and
24 days, respectively (P ¼ .009).
The number of HLA disparities was not associated with
a lower engraftment rate in neither of the 2 trials. CI of
myeloid engraftment in 4/6 and 5-6/6 grafts was 96% and
93% in the GETH-2005 cohort (P¼ .2) and 87% and 89% in the
GETH/GITMO-2008 cohort (P ¼ .4), respectively.
Platelet engraftment
Previous autologous SCT was the only independent vari-
able that inﬂuenced platelet engraftment (RR, 1.74; 95%
conﬁdence interval, 1.14 to 2.67; P ¼ .01). The CI of platelet
engraftment for patients with or without a previous auto-
graft at 180 days was 61% and 79%, at a median time to
platelet recovery of 42 and 48 days, respectively (P ¼ .02).
GVHD
No variable was identiﬁed as a risk factor for acute GVHD
grades II to IV or grades III to IV (Figure 3). The risk of chronic
extensive GVHD was, however, highly inﬂuenced by a center
effect (RR, 5.25; 95% conﬁdence interval, 2.46 to 11.2;
P < .001). The 3-year CI of chronic extensive GVHD for
patients transplanted in the center with the highest
recruitment was 39% compared with 9% in the remaining
centers (P < .001). The 3-year CI of chronic extensive GVHD
for patients in the GETH-2005 and GETH/GITMO-2008
protocols transplanted in the center with the highest
recruitment was 39% and 38%, respectively.
NRM
Advanced disease status at time of transplantation was
the only factor independently associated with an increased
risk of NRM (RR, 1.62; 95% conﬁdence interval, 1.43 to 1.83;
P < .001). The 3-year CI of NRM was 27%, 39%, and 51% for
patients in early, intermediate, or advanced phase of the
disease at time of transplantation, respectively (P ¼ .02).
Relapse
Acute lymphoblastic leukemia diagnosis was the only
factor independently associated with an increased risk of
relapse (RR, 2.76; 95% conﬁdence interval, 1.51 to 5.03;
P ¼ .0009). The 3-year CI of relapse was 28% and 12% for
Table 5
Multivariable Analysis to Identify Variables that Inﬂuenced Different Outcomes
Outcome Variable Favorable Value Relative Risk (95% Conﬁdence Interval) P
Myeloid engraftment CD34þ cells High 1.72 (1.17-2.53) .006
TSCU-GETH protocol GETH-2005 1.66 (1.24-2.22) .0007
Platelet engraftment Previous auto-SCT No 1.74 (1.14-2.67) .01
NRM Disease stage Early 1.62 (1.43-1.83) <.0001
Relapse Diagnosis Other than acute lymphoblastic leukemia 2.76 (1.51-5.03) .0009
EFS Disease stage Early 1.5 (1.1-2.06) .01
J. Sanz et al. / Biol Blood Marrow Transplant 19 (2013) 1387e1392 1391patients with acute lymphoblastic leukemia or other diag-
nosis, respectively (P ¼ .001).
EFS and overall survival
More advanced disease stage at time of transplantation
was the only factor independently associated with worse EFS
(RR, 1.5; 95% conﬁdence interval, 1.1 to 2.06; P ¼ .01) and
overall survival (RR, 1.5; 95% conﬁdence interval, 1.1 to 2.1;
P ¼ .008).
DISCUSSION
This study shows that GVHD prophylaxis with MMF,
together with a slightly reduced dose of ATG, resulted in an
adverse impact on myeloid engraftment both in terms of
time to neutrophil recovery and graft failure rates after
single-unit UCBT (sUCBT). We also conﬁrmed that sUCBT
from unrelated donors using busulfan-based myeloablative
conditioning is a valuable strategy for patients with hema-
tological malignancies. Long-term EFS can be achieved in
a substantial number of patients, especially if transplanted in
an early stage of the disease.
Following standard practice of the GETH and GITMO
groups, the prospective but nonrandomized GETH/GITMO-
2008 trial was designed to perform an historical compar-
ison with the previous GETH-2005 protocol. To reduce the
chance of bias, both protocols used the same conditioning
regimen. Compared with the GETH-2005 trial, the only
changes implemented in the GETH/GITMO-2008 trial were
in the GVHD prophylaxis. These consisted of a replacement of
long-term steroids therapy by a short course of MMF and
a slight dose reduction of ATG. Criteria for patient and unit
selection were unchanged throughout the study period
except for the minimum cell dose requirements that were
slightly modiﬁed for adults in the GETH/GITMO-2008Figure 2. Cumulative incidence of neutrophil recovery after UCBT according to
UCBT protocol.protocol. In this trial, the minimum cell dose required per
unit was TNC > 150  107 and CD34þ cells > 70  105,
regardless of recipient’s body weight. Theoretically, this
change, which would facilitate the unit selection, ensured
a higher minimum cell dose than in the previous trial for
those patients weighting less than 70 kg. In fact, only over-
weight patients could be transplanted with a lower cell dose
requirement than in the prior trial when a more cellular unit
was not available.
The implementation of these modiﬁed criteria was based
on our previous experience, in which the recipient’s weight
was never associated with engraftment [1,12,13]. Neverthe-
less, most patient and transplant characteristics, including
graft cell content, were comparable in the 2 subsequent
trials, except for a signiﬁcantly higher proportion of donor
and recipient HLA disparity in the GETH/GITMO-2008 trial.
An explanation for this ﬁnding is that once demonstrated in
previous studies the lack of an adverse impact of HLA
disparity [1], the priority for selection of CBU switched from
the degree of HLA mismatch to a higher cell dose. This
change in the strategy could have lead to an increased
disparity rate in the GETH/GITMO-2008 cohort. However, the
number of HLA disparities did not affect any outcome,
including myeloid recovery, in any cohort. Due to the study
design, other differences between the 2 groups that could
bias ﬁnal results cannot be ruled out. In this regard, we have
no data on CMV infection, as well as its treatment, that could
potentially affect neutrophil recovery, although the use of
prophylactic valganciclovir was not different in both
protocols.
Myeloid engraftment in the protocol GETH/GITMO-2008
was better than that reported by most multicenter studies
in children [14] and adults [15,16], including those with
double cords [17]. However, engraftment was signiﬁcantlyFigure 3. Cumulative incidence of acute GVHD grades III to IV after UCBT
according to UCBT protocol.
J. Sanz et al. / Biol Blood Marrow Transplant 19 (2013) 1387e13921392worse than that obtained in the previous GETH-2005 trial,
both in terms of CI of engraftment and time to neutrophil
recovery. Considering that apart from a slightly reduced dose
of ATG in the conditioning regimen, the use of MMF as GVHD
prophylaxis was the only substantial modiﬁcation compared
with the GETH-2005 protocol, we hypothesized that this
drug could have a role in hampering engraftment. In fact,
MMF-induced myelosuppression has been previously re-
ported [18] as well as a delay in neutrophil engraftment in
cord blood transplantation with intensive administration of
MMF for GVHD prophylaxis [19]. This observation may be
relevant because MMF is widely used in UCBT prevention of
GVHD due to the concern of a negative effect on neutrophil
engraftment with the use of methotrexate.
In line with our ﬁnding, other UCBT series using MMF-
containing prophylaxis have reported similar rates of
engraftment than that observed in the present study [20,21].
It should be noted that the risk of acute GVHD remained
relatively low and seemed to be unaffected by both the slight
reduction of ATG and the switch from long-term steroids to
MMF. These observations will be considered in future strat-
egies for GVHD prophylaxis in the setting of GETH/GITMO
trials, and a combination of calcineurin inhibitor with a short
course of steroids seems to be a reasonable approach in this
setting.
A major endpoint of our study was to analyze the impact
of GVHD prophylaxis regimen on the risk of GVHD. Although
we have documented an unexpected difference in the re-
ported rates of acute and chronic GVHD between the
different institutions, the risk of acute GVHD grades II to IV
and III to IV and chronic extensive GVHD of GETH-2005 and
GETH/GITMO-2008 protocols was similar across centers. We
have also revised GVHD diagnosis and staging criteria in the
different participating centers without ﬁnding signiﬁcant
differences to explain this ﬁnding.
The objective of decreasing the infectious related mor-
tality was not met, because mortality and causes of death
were not signiﬁcantly different in both trials.Most infectious-
related deaths were microbiologically documented and were
equally distributed in bacterial, fungal, and viral causes in
both trials. Early toxicity of the regimen, measured with the
100-day NRM, remained within the lower range reported in
the literature [14-16], except for a study from the University
of Tokyo [22]. However, nonrelapse-related deaths occurred
later, probably reﬂecting a maintained and deep immuno-
suppression. This could explain, at least in part, why even if
neutrophil recovery was delayed, NRM was not increased in
the most recent protocol.
In conclusion, our study conﬁrms that sUCBT from unre-
lated donors using busulfan-based myeloablative condi-
tioning is a valuable strategy for patients with hematological
malignancies. Long-term disease-free survival can be ach-
ieved in a substantial number of patients, especially if
transplanted in an early stage of the disease. The use of MMF
as GVHD prophylaxis apparently had an adverse effect on
myeloid engraftment, and, therefore, until future studies
clarify this issue, a cautious use of this immunosuppressive
agent is warranted in this setting.
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